The prefilled syringes small molecule market was valued around US$ 12.03 Bn in 2015, accounting for significant market share of the global prefilled syringes market and anticipated to grow at substantial growth rate over the forecast period. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the prefilled syringe small molecule market in U.S. and EU-5 region over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in prefilled syringe small molecule market are presented in the report.
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Drivers and Trends
U.S. and EU-5 market for prefilled syringe small molecule is expected to witness significant growth rate in terms of value owing to the technology innovations in pertaining to prefilled syringes, increasing demand for point of care administration, and change in patient behavior – seeking rapid relief through injectable drug delivery contributes to growth of the U.S. and EU-5 market for prefilled syringe small molecule. To understand and assess opportunities in this market, the report offers market forecast on the basis of therapeutic class and regions. The report provides analysis of the U.S. and EU-5 market for prefilled syringe small molecule in terms of market value (US$ Mn) and volume.
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Segmentation
Based on therapeutic class, the market is segmented into neurology drug, cardiovascular drugs, analgesics, adjuvants. The neurology drugs segment held a significant share of the U.S. and EU-5 prefilled syringes small molecule market. The segment is anticipated to witness high growth during the forecast period. The high growth of the segment is attributed to the popularity of non-availability of many generic equivalent drugs. This segment consists of the most prominent best-selling brand such as Copaxone. Moreover, recently launched neurological small molecule prefilled syringe such as the Glatopa by Sandoz, throw light upon the fact that neurology small molecule drug prefilled syringe are a strong strategic growth driver in the prefilled syringe small molecule space and are here to stay. Both in the U.S. and EU-5, the trend is upwards for neurological and cardiovascular small molecule prefilled syringe owing to the need of availability in emergency situations for self-medication and safe and accurate dose delivery.
U.S. and EU-5 Prefilled Syringe Small Molecule Market: Geographical Outlook
Geographically, the prefilled syringe small molecule market is studied for U.S. and EU-5 region. In the U.S., a key trend in the market has been a rise of generic equivalent availabilities and market exclusivity agreements. Although the generic equivalent availability is comparatively better in the U.S. compared to EU-5, most key players operating in this market believe that further increasing foray of small molecules owing to patent expiry and generic equivalents availability is the key to grow prefilled syringe small molecule market.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=903186
The report includes a competitive landscape for prominent players in the prefilled syringe small molecule market. It has been included to provide a dashboard view of key companies operating in U.S. and EU-5 market for prefilled syringe small molecule. It also includes brief overview of prominent market strategies and SWOT analysis of the main players operational in the U.S. and EU-5 market for prefilled syringe small molecule.
Key Players Mentioned in this Report are:
Key players in the U.S. and EU-5 market for prefilled syringe small molecule are Teva Pharmaceutical Industries Ltd., Hospira, Inc (Now Pfizer, Inc.), Mylan N.V., Fresenius Kabi, Becton, Dickinson and Company and Sanofi.
The U.S. and EU-5 market for prefilled syringe small molecule has been segmented as follows:
U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class
- Glatiramer Acetate
- Cardiovascular Drugs
- Atropine Sulfate
- Verapamil Hydrochloride
- Enoxaparin sodium
- Fondaparinux Sodium
- Nadroparin Calcium
- ketorolac Tromethamine
- Morphine Sulphate
- Dexamethasone Na Po4
- Hydromorphone Hydrochloride
- Water for Injection
- NaCl 0.9%/Saline
- Sodium Hyaluronate
- 25% Dextrose
- Lidocaine Hydrochloride